Template: FDA Form 483 Response Package

This is a ready-to-use structure for a written 483 response. Replace each <<FILL: ...>> placeholder with your own specifics, keep the observation wording exactly as FDA wrote it, and route the package through quality and regulatory before submission. A filled specimen block follows. This is educational structure to adapt, not legal advice; have your own quality and regulatory functions own the content, and verify each cited regulation against the current source.

How to use this template

Respond in writing within 15 business days of the inspection close, because a response received in that window is read together with the Establishment Inspection Report before the agency settles on a classification. Organize the package observation by observation, in the order FDA listed them. For each observation, complete the seven-line block below. Immediate corrections should be substantially complete before you submit, so the block reports done work, not just plans.

Cover letter

<<FILL: COMPANY letterhead>> <<FILL: date>>

<<FILL: District Director / addressee and FDA district address>>

Re: Response to Form FDA 483 issued <<FILL: date>>, <<FILL: facility name and FEI number>>, inspection <<FILL: dates>>.

Dear <<FILL: addressee>>,

<<FILL: COMPANY>> appreciates the observations made during the inspection of <<FILL: facility>>. We take them seriously and have already begun corrective action. This response addresses each observation in the order listed on the Form 483, and for each states our position, the immediate correction taken, the root cause, the systemic preventive action, how we will verify effectiveness, and the timeline. Evidence is attached and referenced inline.

<<FILL: one or two sentences of genuine, non-defensive framing: what the organization understands about the findings as a set, and the senior commitment behind the response>>

Questions may be directed to <<FILL: name, title, contact>>.

Sincerely, <<FILL: signer name, title>> (<<FILL: seniority matched to severity>>)

Per-observation block (repeat for each observation)

Observation <<FILL: n>>: <<FILL: restate the observation verbatim as FDA wrote it>>

Our position: <<FILL: Agree / Agree in part / Factual clarification>>. <<FILL: if agree in part or clarifying, state the specific point, factually, and lead with the substantive response, not the disagreement>>

Immediate correction (completed <<FILL: date>>): <<FILL: exactly what was done to correct the observed condition, with a reference to the attached evidence. If a correction could not be completed in the window, state the interim control protecting product and data in the meantime>>

Root cause: <<FILL: the underlying system failure, with the analysis method named (five whys, fishbone, fault tree). Go past the symptom to why it happened and why it was not detected. Reference the attached analysis>>

Systemic preventive action: <<FILL: the change that prevents recurrence everywhere the same class of problem could exist, with the scope stated as a number (how many systems, lines, or records are in scope) and the assessment that defines it>>

Effectiveness verification: <<FILL: how and when you will confirm the fix held: the method, a measurable acceptance criterion, a named owner, and a time horizon set far enough out to catch a fix that worked on paper but failed in practice>>

Timeline and milestones: <<FILL: dated milestones for any action longer than the window (assessment complete, protocol approved, execution complete, effectiveness check), so a slip in one phase is visible and does not silently consume the whole timeline>>

Attachments: <<FILL: numbered list of the evidence proving each claim in this block>>

Attachment index

Acceptance criteria for the package before you submit

• Each observation is restated verbatim and answered in FDA’s order.
• Each block states a clear position without spending the response arguing characterization.
• Each immediate correction is complete or has a stated interim control, with attached evidence.
• Each root cause reaches a level where the fix is possible and explains why the problem was not detected, not only why it happened.
• Each preventive action names its scope as a number and rests on an assessment, not an assertion.
• Each block includes an effectiveness verification with a measurable acceptance criterion and a time horizon.
• Every claim has a numbered attachment; no claim stands without evidence.
• For any data integrity observation, a retrospective data review is scoped with a population and a decision rule (see the paired retrospective data review report).
• The signer’s seniority matches the severity of the findings.

Policy and regulatory basis

The 483 is issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. The 15-business-day review practice and the Warning Letter process are described in FDA’s Regulatory Procedures Manual, Chapter 4. The underlying cGMP requirements depend on the product: 21 CFR Parts 210 and 211 for drugs, the 21 CFR 600 series for biologics, 21 CFR Part 4 for combination products, and the bioresearch monitoring regulations for clinical and nonclinical work. Data integrity expectations draw on FDA’s 2018 guidance “Data Integrity and Compliance With Drug CGMP” and MHRA’s 2018 “GXP Data Integrity” guidance.

Confirm the current version of each reference before you rely on it. This template does not create or imply any legal position; your legal function advises on admissions and liability, and quality owns the technical content.

Filled specimen (one observation block)

The following shows the block populated for a laboratory data integrity observation, at the depth a reviewer expects. Illustrative numbers; replace with your own.

Observation 1: The audit trail function in the laboratory chromatography data system was disabled, and analysts could delete acquired data files without a record of the deletion.

Our position: Agree.

Immediate correction (completed 12 calendar days after inspection close): The audit trail was enabled across all instances of the chromatography data system and locked at the application administrator level so it cannot be disabled by analyst or laboratory-management roles. The file-delete privilege was removed from all analyst and reviewer roles; only the validated system administrator role retains it, under change control. Access was restricted on the day of the observation as an interim control while the lock was implemented. Configuration record attached (Attachment 1).

Root cause: Fishbone analysis (Attachment 2) identified two converging causes. First, a system design gap: the initial validation did not specify that the audit trail be enabled and locked, so the setting was changeable by routine user roles. Second, an oversight gap: the periodic review did not verify audit-trail status, so the disabled state persisted undetected for an estimated 14 months, being confirmed by the retrospective review.

Systemic preventive action: A configuration baseline specifying required, locked security and audit settings has been created for every GxP computerized system that generates or processes data supporting product-quality decisions; all 17 such systems are being assessed against it; and the periodic-review SOP is being revised to require documented verification of audit-trail and security configuration at each review, with a named owner and frequency (Attachment 4, system inventory with status).

Effectiveness verification: Six months after implementation, Quality will review 100 percent of the in-scope systems for audit-trail and lock status and the periodic-review records for the new check. Acceptance criterion: zero systems with a disabled or unlocked audit trail, and 100 percent of due periodic reviews include the configuration check.

Timeline and milestones: Configuration baseline approved (complete). All 17 systems assessed: 8 weeks. Remediation of nonconforming systems: 14 weeks. Periodic-review SOP revised and trained: 6 weeks. Retrospective data review: 16 weeks. Effectiveness check: month 7.

Attachments: Configuration record (1), root cause analysis (2), revised periodic-review SOP draft (3), system inventory with assessment status (4).

Notice what the filled block does: names a method, gives the scope a number (17 systems), bounds the data exposure (estimated 14 months, being confirmed), states the acceptance criterion in measurable terms, and attaches evidence rather than asserting completion.

Common inspection findings this template prevents

• Correction without a credible root cause, so the agency cannot tell whether recurrence is prevented.
• Fixing the one cited instance while saying nothing about comparable systems, which reads as failing to address the systemic nature of the deficiency.
• Retraining offered as the fix for a design or oversight gap.
• Vague or unrealistic timelines with no milestones.
• Claims of revised procedures and retraining with no attached evidence.
• For a data integrity finding, no retrospective assessment of the historical data the failure could have affected.

How to adapt this template

1. Set your letterhead, addressee, and facility identifiers in the cover letter.
2. Copy the per-observation block once per observation and keep FDA’s exact wording at the top of each.
3. Match the signer’s seniority to severity: a serious response signed by senior management signals leadership ownership.
4. Pair the package with a commitment register (so every dated commitment is tracked to closure) and, for data integrity findings, a retrospective data review report.
5. Have someone independent of the original work, external for serious cases, red-team the draft before submission.
6. Confirm every regulation in the policy basis against the current published version before you rely on it.